Last updated: May 26, 2026
- Dutasteride and tamsulosin hydrochloride are widely sourced actives with mature, global supplier ecosystems. The highest IP and regulatory friction points are (1) branded clinical supply chains with supplier qualification requirements and (2) US FDA expectations for ANDA-ready control strategies for polymorphs, residuals, and impurity profiles.
- Commercially meaningful supplier universe clusters into: API manufacturers (CAS/USP-grade supply), contract manufacturers for solid oral dosage (tablets/capsules), and niche excipient and packaging suppliers. For most entry strategies, the limiting factor is not API availability but regulatory-relevant impurity, genotoxic impurity control, and batch-to-batch consistency.
What suppliers make dutasteride APIs for generic and branded markets?
Which API manufacturers supply dutasteride (CAS 846659-53-8)
Dutasteride API supply typically comes from large-scale specialty generics and fine-chemical groups. In practice, supplier qualification depends on the dossier readiness for ANDA filings and on impurity control (including related substances and residual solvents) consistent with FDA expectations for small-molecule oral drugs.
Supplier categories
- US/EU ANDA-ready API producers that support DMF or CEP-backed documentation packages.
- Contract API producers that supply through intermediaries to distributors and finished-dose CMO/CDMO systems.
- Chinese and Indian scale API manufacturers that provide commercial volumes and support regulatory filings when manufacturing sites and specs align.
What to validate with supplier due diligence
- Impurity profile alignment: dutasteride related substances, residual solvents, heavy metals.
- Genotoxic impurity control: process controls and analytical methods consistent with ICH M7 risk reduction plans.
- Polymorph and solid-state control: consistent particle size distribution and crystallinity where applicable to downstream processing.
- Stability and hold-time: API stability under expected storage and shipping conditions.
Which companies supply dutasteride capsules and tablets (finished dosage)
Finished-dose supply for dutasteride concentrates in oral solid dose CMOs with line capability for capsules or tablets, plus strong experience with controlled moisture and oxygen environments where needed for stability.
Common finished-dose manufacturing footprints
- Gelatin capsule filling lines for dutasteride softgel or capsule presentations
- Tablets for downstream combinations where dutasteride is blended with other actives
- Packaging compatibility with desiccants and moisture barriers where product stability requires it
Key qualification signals buyers use
- Demonstrated control of moisture ingress and desiccant strategy
- Batch record discipline and analytics packages aligned with FDA chemistry expectations
- Experience with cross-linked quality systems for ANDA and NDA supply continuity
Who supplies tamsulosin hydrochloride API and finished oral solid drugs?
Which API suppliers make tamsulosin hydrochloride (CAS 106133-22-4)
Tamsulosin hydrochloride is a high-volume alpha-1A/1D blocker with broad supply availability. Supplier selection is driven by dossier strength, impurity controls, and ability to meet sustained-release formulation constraints (tamsulosin is commonly delivered as an extended-release formulation).
Supplier categories
- Large API producers with established impurity specifications and route control.
- Intermediate and API integrators that deliver site-stable, specification-consistent material.
- Regulatory dossier partners that can provide DMF support for ANDA applicants.
What to validate
- Impurity and residual solvent control consistent with regulatory specs
- Chiral integrity and stereochemical purity where required by manufacturing route
- Particle engineering compatibility with controlled-release matrix systems
Which companies manufacture tamsulosin hydrochloride sustained-release products
The market heavily favors oral sustained-release formats, and supplier qualification targets the ability to control:
- Granulation and blending uniformity
- Polymer hydration and gel layer consistency
- In-process dissolution and release testing
CMO/CDMO capabilities that matter
- Controlled-release matrix manufacturing lines
- In-house or qualified analytical labs for dissolution method execution
- Stability program performance on temperature and humidity stress profiles
How do dutasteride and tamsulosin supply chains differ by regulatory and formulation risk?
Which API-to-finished-dose risks dominate for dutasteride
- Sensitivity to impurity thresholds and analytical method robustness across suppliers
- Stability and solid-state consistency for oral dosing units
- Handling requirements for blending into combination products
Which API-to-finished-dose risks dominate for tamsulosin
- Greater formulation leverage on release kinetics, making API physical properties and batch consistency more determinative
- Dissolution and release test method transfer capability from API lot through finished dose
What excipient and packaging suppliers are used for these drugs’ solid oral dosage forms?
Excipients that frequently constrain supplier qualification
- Film coat systems and polymers for extended release (tamsulosin)
- Capsule shells and fill components (dutasteride where capsule presentations are used)
- Colorants where present in branded products
- Lubricants and disintegrants that do not interfere with release or stability
Packaging suppliers that matter for stability
- Moisture-barrier blister and bottle systems
- Desiccant and seal systems
- Child-resistant packaging where mandated by product labeling standards
Can the same supplier provide both dutasteride and tamsulosin hydrochloride?
Typical market pattern
- Rare at the API level: Many suppliers specialize in one active, with cross-supply only where they have both synthetic routes and regulatory documentation packages.
- More common at the CMO/CDMO level: The same finished-dose manufacturer often handles both products or common combination programs because the tooling is similar for oral solids.
What buyers check when consolidating suppliers
- Shared quality systems and audit readiness across both actives
- Ability to support simultaneous batch scheduling
- Analytical method transfer bandwidth across two distinct chemical platforms
How do buyers evaluate supplier compliance for dutasteride and tamsulosin hydrochloride?
Compliance checklist used in procurement and QA
- GMP certification status and inspection history at the API site
- DMF or CEP documentation readiness for regulatory filings
- Specification control: identity, potency, impurities, residual solvents, particle size
- Batch traceability and change control governance
- Stability data package completeness for the intended shelf life
Commercial due diligence
- Supply continuity risk and capacity
- Allocation practices during shortages
- Lead-time performance and logistics reliability
- Ability to support tech transfer and method validation for ANDA readiness
What generic entry risks exist if supplier specs do not match?
For dutasteride
- Failure to meet impurity and related substances thresholds can block ANDA bioequivalence and stability comparability acceptance.
- Inconsistent particle properties can affect capsule fill uniformity and finished-dose dissolution.
For tamsulosin
- Variation in API physical properties and impurity profile can shift dissolution or sustained-release behavior.
- Method transfer issues for dissolution and release testing can delay regulatory acceptance.
Key Takeaways
- Dutasteride and tamsulosin hydrochloride have broad API and finished-dose supply ecosystems; supplier selection is less about existence of supply and more about dossier readiness and impurity control.
- Procurement and QA emphasis should go to impurity and residual solvent control, genotoxic risk controls, solid-state and physical property consistency, and the ability to support method transfers for dissolution/release testing (especially for tamsulosin).
- Consolidating suppliers is more feasible for finished-dose CMOs than for API manufacturers, unless the API producer has both routes and robust regulatory documentation for both actives.
FAQs
1) What documentation is typically required from dutasteride or tamsulosin API suppliers for regulatory submissions?
Commonly: GMP evidence, DMF/ASMF readiness where applicable, full impurity and residual solvent specs, analytical method summaries, and stability data packages aligned to intended shelf life.
2) Are dutasteride and tamsulosin hydrochloride commonly supplied as finished combination products or as standalone generics?
Both routes exist: standalone oral products and combination offerings. Finished-dose CMO ecosystems frequently support both models, while API sourcing is often specialized.
3) What are the main quality parameters buyers should demand for tamsulosin hydrochloride extended-release tablets/capsules?
Dissolution/release profile consistency, polymer and matrix uniformity controls, API particle properties, impurity profile, and residual solvents.
4) How do API impurity profiles impact ANDA approval timelines?
Non-alignment with established impurity thresholds and inadequate analytical method robustness can trigger extended method validation, additional stability studies, or delays in regulatory review.
5) What supplier risks matter most during API shortages for these actives?
Allocation practices, lead-time volatility, and batch-to-batch specification drift that can destabilize formulation release and stability.
References (APA)
No sources were provided in the prompt, and no authoritative supplier lists, DMF/CEP registries, or FDA Orange Book/API data were cited.
